[0011a] In one aspect, the present disclosure refers to the use of an isolated peptide for the preparation of a medicament for the inhibition of angiogenesis in a patient in need, wherein the peptide comprises the amino acid sequence of KFARLWTEIPTAIT (SEQ ID NO: 1) or FTEIPTI (SEQ ID NO: 3).

What is Claimed:

1. Use of an isolated peptide for the preparation of a medicament for the inhibition of angiogenesis in a patient in need, wherein the peptide comprises the amino acid sequence of KFARLWTEIPTAIT (SEQ ID NO: 1) or FTEIPTI (SEQ ID NO: 3).

2. The use of claim 1 where the patient is suffering from a disorder associated with VEGF-induced permeability or cancer.

3. The use of claim 1 wherein the patient is suffering from visual impairment or vision loss (blindness), macular degeneration, central retinal vein occlusion, branch retinal venin occlusion proliferative diabetic retinopathy, neovascular age-related macular degeneration (AMD), retinopathy of prematurity, ischemic retinopathy, intraocular neovascularization, corneal neovascularization, retinal neovascularization, choroidal neovascularization, diabetic macular edema, diabetic retina ischemia, diabetic retinal edema, and proliferative diabetic retinopathy, rubeosis iridis, neovascular glaucoma, retinoblastoma, uveitis and corneal graft neovascularization.

4. The use of any one of claims 1-3 wherein the peptide is linked to a carrier peptide.

5. The use of claim 4 wherein the carrier peptide is antennapedia peptide (AP), antennapedia peptide, penetratin peptide, TAT, tranportan or polyarginine.

6. The use of claim any one of claims 1-5, wherein the peptide is conjugated to a fatty acid.

7. The use of claim 6, wherein the peptide is myristoylated.

8. The use of any one of claims 1-7, wherein the isolated peptide is to be administered in combination with one or more VEGF inhibitors.

9. The use of any one of claims 1-7, wherein the isolated peptide is to be administered in combination with laser treatment of eye disease.

10. The use of any one of claims 1-7, wherein the isolated peptide is to be administered in combination with a steroid.

11. The use of any one of claims 1-10, wherein the isolated peptide, VEGF inhibitor or steroid is to be delivered via intravitreal injection or topically.